COVID-19: ‘We might not be in a great spot in the fall’: Moderna CEO


The majority of Moderna’s (MNRA) revenue comes from governments abroad — which are bracing are for an ongoing need for COVID-19 vaccines this year. While the U.S. waits on funding and for the U.S. Food and Drug Administration (FDA) to decide on which virus strain to attack through boosters, Moderna and other vaccine companies are…

Thanks for reading The LBM Daily.
Join LBM Daily Premium or log in to continue reading.
Login Join Now

Articles You May Like

Limited Time 15% Promo!
Have homebuyers adapted to higher interest rates?
Climate Change May Cut U.S. Forest Inventory by a Fifth This Century
At IBS, experts point to downturn this year, recovery in 2024
‘Drought Profiteers’ Under Fire as Wall Street Targets Colorado River Water
Stocks drift as Wall Street waits for Fed’s latest rate hike